Morepen Laboratories 130-138 Buy Range: Key Levels

Why Morepen Laboratories is trending right now

Morepen Laboratories (NSE: MOREPENLAB, BSE: 500288) has become a high-chatter pharma name after a sharp pullback. Multiple social threads discuss a “buy the dip” range around ₹130-₹138. The posts largely connect this range to widely shared support and pivot levels from technical summaries. At the same time, “November results” is repeatedly mentioned in comment sections, adding an event-driven angle to the debate. Much of that results discussion appears tied to old corporate calendar entries being reshared. Several users are also comparing conflicting signals from different “ratings” cards. One set of cards says “Buy zone” for near-term and long-term, while another popular tracker shows “Hold.” The overall tone online is split between dip-buyers and traders wary of the speed of the fall.

The price action that triggered the dip-buy narrative

The pullback is central to why ₹130 became a focal point for traders. On NSE EOD (09-Oct-2026), social posts cite the stock opening at ₹138.50, hitting a high of ₹141.96, and then dropping to a low of ₹127.14 before closing near ₹129.55. Those same posts describe the day’s fall as about 5.13% around ₹129.55. Another snapshot in the shared context shows the stock last traded at ₹127.83 with an intraday range of ₹123.82 to ₹133.70, down ₹1.72 (1.33%). A separate “as of 13 Oct 2026” line pegs the share price at ₹121.4, showing how quickly the reference point can shift between feeds and timestamps. Regardless of the exact snapshot, the common thread is a fast move down from recent highs. Users are treating the volatility itself as a signal to wait for stabilization near support. That is why the ₹130-₹138 band is being discussed as a near-term decision zone rather than a single precise level.

Technical levels being repeated most often online

A widely shared technical summary lists a pivot near ₹139.10, with the first support at ₹130.71. The same summary shows second and third supports at ₹124.88 and ₹116.49. On the upside, it lists resistance levels near ₹144.93, ₹153.32, and ₹159.15. With the close around ₹129.55 in the posts, the price sat just below the first support level shared, which is why ₹130 became the anchor for many threads. Separately, another set of pivot points circulating online lists a daily pivot of ₹131.69 with R1 at ₹133.67 and S1 at ₹129.71. The overlap between S1 near ₹129.71 and the other support near ₹130.71 reinforces the same zone. Many comments simplify the map into two bands - ₹124-₹131 as immediate support and ₹139-₹145 as the first area where sellers may reappear. That simplification explains why discussions keep returning to “hold ₹130” and “reclaim ₹139.”

Why the ₹130-₹138 band became the “decision zone”

Several threads frame ₹130-₹138 as the near-term dip-buy range because price moved back toward first support after a reversal. In those posts, ₹130 is treated as the line where buyers must show up to slow down the decline. ₹138 is often mentioned because it is close to the prior open zone cited on 09-Oct and sits below the pivot area shared as ₹139.10. This creates a simple trading narrative - buy interest near support, confirmation only if price moves back toward the pivot. Posters also mention CPR and pivot signals being “below,” which they interpret as a headwind until the stock regains the pivot zone. Some users prefer waiting for the price to hold above the support for more than a single session because of the wide swings. Others are willing to stagger entries across the band to manage timing risk. The repeated theme is not certainty about direction, but clarity about where the market is likely to react. That is why the band is framed as a decision zone rather than a guaranteed “buy range.”

The bearish counter-view highlighted in the same threads

Not all posts support dip-buy calls, and the bearish counter-view is also visible. Some users point to “bearish positioning signals” and the speed of the fall from the recent peak as reasons to stay cautious. The argument is that sharp reversals can invite selling pressure on every bounce, especially if price remains below pivot and CPR levels referenced in the posts. In this view, a move toward ₹139-₹145 may bring sellers back, aligning with the first resistance level near ₹144.93. A Q-and-A snippet in the context also references an older technical read where Morepen Labs was described as being in a bearish trend on 19 Nov 2025, with bearish MACD and moving averages and underperformance against the Sensex. While that date is not current, it gets reshared and influences sentiment in comment threads. Traders using this framing focus on whether ₹130 breaks decisively, which would shift attention to the next support around ₹124.88. They also treat the mixed signals across different trackers as a reason to reduce conviction. Overall, the bearish view in the chatter is about structure and momentum, not about new fundamental negatives.

“November results” confusion - what people are actually sharing

The repeated mention of “November results” is largely explained by old corporate calendar entries being reposted. One board meeting line in the shared context shows “Date: 07 Nov ’25” and “Ex Date: 14 Nov ’25” for “Quarterly Results.” Another schedule table lists “Nov 13, 2025” (announced on Nov 6, 2025) as a board meeting for quarterly results. Separately, a Q-and-A style snippet claims the “next results date” as August 4, 2026. That August timing is also consistent with another calendar entry showing an Aug 3, 2026 board meeting for quarterly results. Adding to the mix, another line in the context says “Next results board meeting 3 Nov 2026,” which brings November back into the conversation, but for a different year. The overlap of older November 2025 entries, August 2026 references, and a November 2026 meeting line creates easy confusion for anyone searching “November results date.” The key point from the threads is not a confirmed single date, but that multiple calendar snippets are circulating without clear timestamp context.

Hold versus Buy - why ratings are being debated

Another reason the stock is trending is the split between “Hold” and “Buy” narratives in popular trackers. MarketsMOJO is cited as rating the stock “Hold,” last updated on 04 August 2026. At the same time, separate “expert verdict” cards circulating online describe both near-term and long-term zones as “Buy.” Those verdict cards also claim an “entered Buy zone” on 04 Aug ’26 at ₹69.18. Some commenters treat the presence of both signals as confirmation that the stock is still investable, but with near-term caution. Others argue that mixed ratings should be read as uncertainty, especially during volatile pullbacks. A “#KnowBeforeYouInvest” style snippet lists “Good quarterly growth in the recent results” as a strength, which supports the optimistic camp. However, the same results discussion includes a note of concern about sustainability, given historically modest performance. The result is a market conversation that is less about one definitive rating and more about how each user weighs technical levels versus recent operating momentum. In practical terms, the ratings debate is reinforcing attention on the next results window and the ₹130-₹139 technical area.

The financial numbers most cited to justify optimism

Where fundamentals are discussed, the most repeated reference is to strong Q1 FY27 performance. The shared context describes Morepen Laboratories’ latest Q1 FY27 results as strong, with a 34.07% revenue increase and a 424.65% rise in net profit, described as a significant turnaround. The same snippet also flags concerns about whether the growth rate is sustainable. In the “News” lines being circulated, consolidated June 2026 net sales are cited at Rs 570.13 crore, up 34.07% year-on-year. Standalone June 2026 net sales are cited at Rs 541.04 crore, up 38.27% year-on-year. Additional cited data points include standalone March 2026 net sales at Rs 462.81 crore, up 21.17% year-on-year, and consolidated March 2026 net sales at Rs 484.72 crore, up 4.05% year-on-year. Consolidated December 2025 net sales are cited at Rs 484.16 crore, up 6.93% year-on-year. These figures are used in threads to argue that the pullback is happening alongside improving operating performance, which encourages dip-buying interest. At the same time, posters often separate “good numbers” from “good timing,” pointing back to the need for price stabilization around support.

What traders say they are watching next

Across threads, the most repeated near-term plan is to watch whether ₹130 holds and whether price can reclaim the pivot around ₹139.10. The ₹130-₹138 area is treated as a zone for stabilization after wide intraday swings, rather than a single tick-based entry. If price remains below the pivot and below CPR as referenced in posts, some traders expect selling pressure to persist on pullbacks. If a bounce develops, the first resistance zone discussed is near ₹144.93, which posters link to where sellers may reappear. On the downside, the immediate support band repeated most often is ₹124-₹131, combining the different support and S1 figures shared online. Several comments also reference the broader year range, shown in the context as roughly ₹33 to ₹151, to underline how stretched moves can be in both directions. The common takeaway from the chatter is that the market is seeking a clearer base after a sharp reversal. Until then, the discussion is likely to stay anchored on the same three themes - support near ₹130, pivot near ₹139, and clarity on the next results-related meeting date being circulated.